ClinicalTrials.gg
TerminatedNCT01001221Updated Sep 11, 2013Results posted

Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor

A Phase 1/2 interventional study of cabazitaxel and gemcitabine in Neoplasms, Malignant, sponsored by Sanofi. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-09-11.

Sponsored by Sanofi · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Maximum tolerated dose not able to be determined

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Primary Objectives:

  • Study part 1: To determine the Maximum Tolerated Dose (MTD) and the Dose Limiting Toxicities (DLTs) of cabazitaxel administered as a 1-hour infusion in combination with gemcitabine, every 3 weeks in patients with advanced solid malignancies.
  • Study part 2: To determine the antitumor activity of cabazitaxel in combination with gemcitabine, in an additional extended cohort of 15 patients with advanced solid malignancies treated with the defined MTD, as assessed by objective response rate (ORR) according to the revised guideline for Response Evaluation Criteria in Solid Tumours (RECIST 1.1 criteria).

Secondary Objectives:

  • To assess the safety profile of the combination regimen of cabazitaxel with gemcitabine.
  • To assess the pharmacokinetics (PK) of cabazitaxel, gemcitabine and its metabolite 2',2' difluorodeoxyuridine (dFdU) when given in combination.
  • To determine Time to Progression (TTP), Objective Response Rate (ORR), and Duration of Response (DR), in the extended cohort of patients treated at the MTD in Part 2 of the study and the patients who received the MTD in Part 1 component.

For study part 1, dose levels were to be escalated according to predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 2 patients developed a DLT during the first 3 weeks of treatment. There was no further dose escalation when this dose was achieved. The MTD was defined as the highest dose at which 0 or 1 of 3 to 6 patients, respectively, experienced DLT during the first 3 weeks of treatment.

Read the detailed description

The study consisted of a screening phase (maximum length of 21-day), a treatment phase with 21-day treatment cycles and a 30-day follow-up visit after the last dose of study medication.

The cut-off date for study part 1 was when last participant completed the first treatment cycle and the subsequent 30 days follow-up.

The cut off date for study part 2 was when all participants experienced disease progression, unacceptable toxicity, consent withdrawal or the last participant had completed 26 weeks or 6 cycles on study treatment, whichever came first.

Participants could continue to be treated on study as long as they were benefiting from study treatment and had not met study withdrawal criteria. After withdrawal from study treatment, further treatment, if any, was at the discretion of the Investigator.

02

Conditions studied

  • Neoplasms, Malignant

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 19 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed advanced solid that is or unresectable, and for which standard curative measures do not exist.

Exclusion criteria

Exclusion criteria:

  • (ECOG) performance status (PS) > or =2
  • Anticipation of need for a major surgical procedure or radiation therapy during the study treatment
  • Absence of completion of all prior chemotherapy, biological therapy, targeted non-cytotoxic therapy > or = 3 weeks; and radiotherapy > or = 4 weeks prior to registration. For part 2 only, prior treatment with radiotherapy, chemoembolization therapy, or cryotherapy is allowed if these therapies are not directed to the areas of being used for the purposes of this protocol. (4 weeks of is required prior to start the treatment in Part 2)
  • Concurrent treatment in another clinical trial or with any other cancer therapy or patients planning to receive these treatments during the study
  • Other concurrent serious illness or medical condition, including active infection or (HIV) disease
  • History of any other with the exception of adequately treated basal cell or squamous cell skin cancer, or in situ carcinoma of the cervix uteri
  • Patients without resolution of all toxic effects (excluding alopecia) of any prior therapy to grade \< or = 1 by National Cancer Institute's (NCI-CTCAE), version 3.0 or to within the limits listed in the specific inclusion/exclusion criteria
  • Other severe acute or chronic medical or psychiatric condition, or significant laboratory abnormality requiring further investigation that may cause undue risk for the patient's safety, inhibit protocol participation, or interfere with interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study
  • Symptomatic or . Patients with asymptomatic or stable brain metastases are allowed
  • Women of not protected by highly effective method of birth control. All patients of childbearing potential that do not have a negative pregnancy test within the 7 days prior to registration
  • Patients who are pregnant or breastfeeding
  • For part 2, absence of measurable disease as defined by the most current version of the (RECIST) 1.1. For the Part 1 component, patients with non-measurable disease are accepted
  • Inadequate bone marrow or liver or renal organ function
  • Any condition which is considered a to gemcitabine in the local labelling
  • Prior treatment with cabazitaxel within the last 2 years
  • History of severe grade 3 or 4 to taxanes, Polysorbate-80, or to compounds with similar chemical structures

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Cabazitaxel + gemcitabine

    Cabazitaxel and gemcitabine on Day 1 then gemcitabine alone on Day 8 every 3 weeks until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision. On Day 1, cabazitaxel was given either first followed by gemcitabine (part 1a) or after gemcitabine with 1 hour gap between the two infusions (part 1b). Required premedication with antihistamine, corticosteroid and H2 antagonist was administered intravenously 30 minutes before each dose of cabazitaxel.

    Drug: cabazitaxel · Drug: gemcitabine

Interventions

  • Pharmaceutical form: 60 mg/1.5 ml concentrate solution for infusion Route of administration: Intravenous infusion over 60 minutes Dosage: * Study part 1: 15, 20 or 25 mg/m\^2 according to pre-defined dose escalation schedule * Study part 2: MTD as determined in Study part 1

    Also known as: XRP6258, Jevtana

  • Pharmaceutical form: According to United States Package Insert (USPI) Route of administration: Intravenous infusion over 30 minutes Dosage: * Study part 1: 700, 900 or 1000 mg/m\^2 according to pre-defined dose escalation schedule * Study part 2: MTD as determined in Study part 1.

    Also known as: Gemzar

06

What researchers measure

Primary outcomes

  1. Participants With Dose Limiting Toxicities During Dose Escalation

    Dose Limiting Toxicities (DLTs) were defined as clinical adverse events (AE) or laboratory abnormalities considered drug-related as assessed by the Investigator or Sponsor, and achieving a Common Terminology Criteria for Adverse Events v3.0 (CTCAE) severity rating of severe (3) or life-threatening (4).

    Time frame: Day 1 to Day 21 of the first treatment cycle

  2. Objective Response Rate With MTD

    Objective response was defined as a confirmed complete response (CR) or a confirmed partial response (PR) during the treatment period, based on RECIST 1.1, as assessed by the Investigator. CR: Disappearance of all target lesions, all non-target lesions, and no new lesion. Any pathological lymph nodes must have had reduction in the short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesion. The objective response rate (ORR) was to be calculated as the proportion of participants with confirmed objective response relative to the total number of participants in the analysis population. Due to the inability to determine MTD during the study part 1, the analysis was not performed.

    Time frame: Fron Day 1 up to a maximum of 12 months

Secondary outcomes

  1. Time To Progression With MTD

    Time to progression (TTP) was defined as the time from first treatment administration to first documentation of RECIST-defined objective tumor progression (\>=20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the appearance of \>=1 new lesion and/or unequivocal progression of existing non-target lesions). Median TTP was to be estimated using the Kaplan-Meier method. Due to the inability to determine MTD during the study part 1, the analysis was not performed.

    Time frame: Fron Day 1 up to a maximum of 12 months

  2. Duration of Response With MTD

    Duration of Response (DR) was defined as the time from the first documentation of RECIST-defined objective tumor response to the first documentation of RECIST-defined objective tumor progression or death. Median DR was to be estimated using the Kaplan-Meier method. Due to the inability to determine MTD during the study part 1, the analysis was not performed.

    Time frame: Fron Day 1 up to a maximum of 12 months

  3. Participants With Adverse Events

    Summary of participants with adverse events (AEs) according to severity and relationship to study drug as assessed by the investigator. The National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE), version 3.0 was used to grade the severity of AE. Treatment-emergent adverse events (TEAEs) are AEs that occurred or worsened from start of treatment up to 30 days after treatment ceased. NCI CTCAE v.3.0 grade 3 =severe and grade 4= life-threatening or disabling.

    Time frame: from first dose of study medication up to 30 days after the last dose of study medication (maximum follow-up of 68 weeks)

  4. Pharmacokinetic of Cabazitaxel on Cycle 1: Maximum Plasma Concentration Observed (Cmax)

    Blood samples for cabazitaxel assay were collected during cycle 1 and cabazitaxel plasma concentrations were determined using a validated liquid chromatography with tandem mass spectometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1 ng/mL. Pharmacokinetic (PK) parameters were calculated from plasma concentrations using non-compartmental analysis.

    Time frame: before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion

  5. Pharmacokinetic of Cabazitaxel on Cycle 1: Time to Maximum Concentration (Tmax)

    Time frame: before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion

  6. Pharmacokinetic of Cabazitaxel on Cycle 1: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)

    Area under the plasma concentration versus time curve calculated using the trapezoidal method from time 0 to the last measurable concentration at time t.

    Time frame: before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion

  7. Pharmacokinetic of Cabazitaxel on Cycle 1: Area Under the Time Concentration Curve (AUC)

    Area under the plasma concentration versus time curve extrapolated to infinity

    Time frame: before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion

  8. Pharmacokinetic of Cabazitaxel on Cycle 1: Terminal Half-life (t1/2z)

    Time frame: before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion

  9. Pharmacokinetic of Cabazitaxel on Cycle 1: Total Plasma Clearance (CL)

    Time frame: before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion

  10. Pharmacokinetic of Cabazitaxel on Cycle 1: Volume of Distribution at Steady State (Vss)

    Time frame: before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion

  11. Pharmacokinetic of Cabazitaxel on Cycle 1: Total Plasma Clearance Normalized to Body Surface Area (CL/BSA)

    Time frame: before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion

  12. Pharmacokinetic of Cabazitaxel on Cycle 1: Volume of Distribution at Steady State Normalized to Body Surface Area (Vss/BSA)

    Time frame: before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion

  13. Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Maximum Plasma Concentration Observed (Cmax)

    Blood samples for gemcitabine assay were collected on Day 1 of cycle 1 at the following timepoints: * Cabazitaxel + Gemcitabine: prior the start of cabazitaxel infusion, immediately before the end of gemcitabine infusion, 15, 30 minutes, 1.5, 3.5 and 22.5 hours after the end of gemcitabine infusion; * Gemcitabine + cabazitaxel: prior the start of gemcitabine infusion, immediately before the end of gemcitabine infusion, 15, 30 minutes, 1, 1.5, 2.5, 9 and 23.5 hours after the end of cabazitaxel infusion; Gemcitabine plasma concentrations were determined using validated LC-MS/MS methods with a LLOQ of 50 ng/mL. PK parameters were calculated from plasma concentrations using non-compartmental analysis.

    Time frame: 7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1

  14. Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Time to Maximum Concentration (Tmax)

    Time frame: 7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1

  15. Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)

    Time frame: 7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1

  16. Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Area Under the Time Concentration Curve (AUC)

    Time frame: 7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1

  17. Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Terminal Half-life (t1/2z)

    Time frame: 7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1

  18. Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Total Plasma Clearance (CL)

    Time frame: 7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1

  19. Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Volume of Distribution at Steady State (Vss)

    Time frame: 7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1

  20. Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Total Plasma Clearance Normalized to Body Surface Area (CL/BSA)

    Time frame: 7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1

  21. Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Volume of Distribution at Steady State Normalized to Body Surface Area (Vss/BSA)

    Time frame: 7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1

  22. Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Maximum Plasma Concentration Observed (Cmax)

    Blood samples for gemcitabine assay were collected on Day 8 of cycle 1 at the following timepoints: * Cabazitaxel + Gemcitabine: prior the start of infusion, immediately before the end of infusion, 15, 30 minutes, 1.5, 3.5 and 22.5 hours after the end of infusion; * Gemcitabine + cabazitaxel: prior the start of infusion, immediately before the end of infusion, 15, 30 minutes, 1, 1.5, 2.5, 9 and 23.5 hours after the end of infusion; Gemcitabine plasma concentrations were determined using validated LC-MS/MS methods with a LLOQ of 50 ng/mL. PK parameters were calculated from plasma concentrations using non-compartmental analysis.

    Time frame: 7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1

  23. Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Time to Maximum Concentration (Tmax)

    Time frame: 7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1

  24. Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)

    Time frame: 7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1

  25. Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Terminal Half-life (t1/2z)

    Time frame: 7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1

  26. Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Area Under the Time Concentration Curve (AUC)

    Time frame: 7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1

  27. Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Total Plasma Clearance (CL)

    Time frame: 7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1

  28. Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Volume of Distribution at Steady State (Vss)

    Time frame: 7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1

  29. Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Total Plasma Clearance Normalized to Body Surface Area (CL/BSA)

    Time frame: 7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1

  30. Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Volume of Distribution at Steady State Normalized to Body Surface Area (Vss/BSA)

    Time frame: 7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1

  31. Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Maximum Plasma Concentration Observed (Cmax)

    Blood samples collected for gemcitabine assay were used to assay gemcitabine metabolite, 2',2' difluorodeoxyuridine(dFdU). 2',2' difluorodeoxyuridine plasma concentrations were determined using validated LC-MS/MS methods with a LLOQ of 50 ng/mL. PK parameters were calculated from plasma concentrations using non-compartmental analysis.

    Time frame: 7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1

  32. Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Time to Maximum Concentration (Tmax)

    Time frame: 7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1

  33. Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)

    Time frame: 7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1

  34. Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Terminal Half-life (t1/2z)

    Time frame: 7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1

  35. Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Area Under the Time Concentration Curve (AUC)

    Time frame: 7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1

  36. Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Maximum Plasma Concentration Observed (Cmax)

    Blood samples collected for gemcitabine assay were used to assay gemcitabine metabolite, 2',2' difluorodeoxyuridine(dFdU). 2',2' difluorodeoxyuridine plasma concentrations were determined using validated LC-MS/MS methods with a LLOQ of 50 ng/mL. PK parameters were calculated from plasma concentrations using non-compartmental analysis.

    Time frame: 7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1

  37. Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Time to Maximum Concentration (Tmax)

    Time frame: 7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1

  38. Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)

    Time frame: 7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1

  39. Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Terminal Half-life (t1/2z)

    Time frame: 7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1

  40. Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Area Under the Time Concentration Curve (AUC)

    Time frame: 7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1

  41. Pharmacokinetic of Gemcitabine on Cycle 1: Ratio Day 1/Day 8 for AUClast and AUC

    Ratio Day 1/Day 8 for AUClast and AUC were calculated to assess the effect of cabazitaxel on gemcitabine exposure.

    Time frame: Day 1 (7 to 9 timepoints from start of infusion up to 24h hours after the end of infusion) and Day 8 (7 to 9 timepoints from start of infusion up to 24h hours after the end of infusion)

07

Results

Posted Sep 11, 2013
Limitations and caveats
Pharmacokinetic results need to be confirmed due to the limited data available.

Participant flow

Participants were enrolled in 4 sites in the United States. Since it was not possible to determine the maximum Tolerated Dose (MTD) in study part 1, no participant was enrolled in study part 2 and the study was stopped.

Participant flow — Overall Study
MilestonePart 1: Cabazitaxel + Gemcitabine Dose Level 0Part 1: Cabazitaxel + Gemcitabine Dose Level -1Part 1: Cabazitaxel + Gemcitabine Dose Level -2Part 1: Gemcitabine + Cabazitaxel Dose Level 0Part 2: Cabazitaxel + Gemcitabine MTD
Started55360
Treated55260
Completed 1st treatment cycle55260
Completed00000
Not completed55360
Withdrew: Adverse event12020
Withdrew: Disease progression32240
Withdrew: Other11000
Withdrew: Not treated; protocol exclusion00100

Outcome measures

PrimaryParticipants With Dose Limiting Toxicities During Dose Escalation

Dose Limiting Toxicities (DLTs) were defined as clinical adverse events (AE) or laboratory abnormalities considered drug-related as assessed by the Investigator or Sponsor, and achieving a Common Terminology Criteria for Adverse Events v3.0 (CTCAE) severity rating of severe (3) or life-threatening (4).

Time frame:
Day 1 to Day 21 of the first treatment cycle
Reported as:
Number · participants
Participants With Dose Limiting Toxicities During Dose Escalation
participantsCabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Participants With Dose Limiting Toxicities During Dose Escalation2222
SecondaryTime To Progression With MTD

Time to progression (TTP) was defined as the time from first treatment administration to first documentation of RECIST-defined objective tumor progression (\>=20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the appearance of \>=1 new lesion and/or unequivocal progression of existing non-target lesions). Median TTP was to be estimated using the Kaplan-Meier method. Due to the inability to determine MTD during the study part 1, the analysis was not performed.

Time frame:
Fron Day 1 up to a maximum of 12 months

No measurements were reported for this outcome.

SecondaryDuration of Response With MTD

Duration of Response (DR) was defined as the time from the first documentation of RECIST-defined objective tumor response to the first documentation of RECIST-defined objective tumor progression or death. Median DR was to be estimated using the Kaplan-Meier method. Due to the inability to determine MTD during the study part 1, the analysis was not performed.

Time frame:
Fron Day 1 up to a maximum of 12 months

No measurements were reported for this outcome.

SecondaryParticipants With Adverse Events

Summary of participants with adverse events (AEs) according to severity and relationship to study drug as assessed by the investigator. The National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE), version 3.0 was used to grade the severity of AE. Treatment-emergent adverse events (TEAEs) are AEs that occurred or worsened from start of treatment up to 30 days after treatment ceased. NCI CTCAE v.3.0 grade 3 =severe and grade 4= life-threatening or disabling.

Time frame:
from first dose of study medication up to 30 days after the last dose of study medication (maximum follow-up of 68 weeks)
Reported as:
Number · participants
Participants With Adverse Events
participantsCabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Any AE5526
Any TEAE5526
- Drug-related TEAE5526
Grade 3-4 TEAE5526
- Grade 3-4 drug-related TEAE4526
Serious TEAE5224
- Drug-related serious TEAE3223
AE leading to drug withdrawn2202
- Drug-related AE leading to drug withdrawn0201
AE leading to death1000
AE leading to dose reduction3424
AE leading to dose delay4214
Post-hocParticipant Best Response as Per the Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1

Participant Best response was assessed by investigator using the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1: * Complete response (CR): Disappearance of all target lesions, all non-target lesions, and no new lesion. Any pathological lymph nodes must have had reduction in the short axis to \<10 mm: * Partial response (PR): At least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesion; * Progressive disease (PD): \>=20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since treatment started or the appearance of \>=1 new lesion and/or unequivocal progression of existing non-target lesions; * Stable disease (SD): not a CR, PR or PD.

Time frame:
Up to a maximum of 22 cycles (median 4 cycles)
Reported as:
Number · participants
Participant Best Response as Per the Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1
participantsCabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Complete response0000
Partial response1101
Stable disease2303
Progressive disease1122
Not evaluable1000
SecondaryPharmacokinetic of Cabazitaxel on Cycle 1: Maximum Plasma Concentration Observed (Cmax)

Blood samples for cabazitaxel assay were collected during cycle 1 and cabazitaxel plasma concentrations were determined using a validated liquid chromatography with tandem mass spectometry (LC-MS/MS) method with a lower limit of quantification (LLOQ) of 1 ng/mL. Pharmacokinetic (PK) parameters were calculated from plasma concentrations using non-compartmental analysis.

Time frame:
before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion
Reported as:
Mean · ng/ml
Pharmacokinetic of Cabazitaxel on Cycle 1: Maximum Plasma Concentration Observed (Cmax)
ng/mlCabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Pharmacokinetic of Cabazitaxel on Cycle 1: Maximum Plasma Concentration Observed (Cmax)123 ± 43.7150 ± 80.9273 ± 21.9118 ± 43.9
SecondaryPharmacokinetic of Cabazitaxel on Cycle 1: Time to Maximum Concentration (Tmax)
Time frame:
before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion
Reported as:
Median · hours (hr)
Pharmacokinetic of Cabazitaxel on Cycle 1: Time to Maximum Concentration (Tmax)
hours (hr)Cabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Pharmacokinetic of Cabazitaxel on Cycle 1: Time to Maximum Concentration (Tmax)1.00 (0.92 to 1.05)0.94 (0.87 to 0.95)0.94 (0.88 to 1.00)0.93 (0.92 to 1.03)
SecondaryPharmacokinetic of Cabazitaxel on Cycle 1: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)

Area under the plasma concentration versus time curve calculated using the trapezoidal method from time 0 to the last measurable concentration at time t.

Time frame:
before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion
Reported as:
Mean · ng*hr/ml
Pharmacokinetic of Cabazitaxel on Cycle 1: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)
ng*hr/mlCabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Pharmacokinetic of Cabazitaxel on Cycle 1: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)556 ± 500352 ± 101344 ± 114315 ± 208
SecondaryPharmacokinetic of Cabazitaxel on Cycle 1: Area Under the Time Concentration Curve (AUC)

Area under the plasma concentration versus time curve extrapolated to infinity

Time frame:
before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion
Reported as:
Mean · ng*hr/ml
Pharmacokinetic of Cabazitaxel on Cycle 1: Area Under the Time Concentration Curve (AUC)
ng*hr/mlCabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Pharmacokinetic of Cabazitaxel on Cycle 1: Area Under the Time Concentration Curve (AUC)876 ± 730420 ± 77.3462 ± 156306 ± 50.1
SecondaryPharmacokinetic of Cabazitaxel on Cycle 1: Terminal Half-life (t1/2z)
Time frame:
before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion
Reported as:
Mean · hours (hr)
Pharmacokinetic of Cabazitaxel on Cycle 1: Terminal Half-life (t1/2z)
hours (hr)Cabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Pharmacokinetic of Cabazitaxel on Cycle 1: Terminal Half-life (t1/2z)92.1 ± 40.388.3 ± 35.175.6 ± 27.870.3 ± 43.1
SecondaryPharmacokinetic of Cabazitaxel on Cycle 1: Total Plasma Clearance (CL)
Time frame:
before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion
Reported as:
Mean · L/hr
Pharmacokinetic of Cabazitaxel on Cycle 1: Total Plasma Clearance (CL)
L/hrCabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Pharmacokinetic of Cabazitaxel on Cycle 1: Total Plasma Clearance (CL)61.0 ± 38.464.3 ± 16.259.5 ± 6.3890.8 ± 7.15
SecondaryPharmacokinetic of Cabazitaxel on Cycle 1: Volume of Distribution at Steady State (Vss)
Time frame:
before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion
Reported as:
Mean · L
Pharmacokinetic of Cabazitaxel on Cycle 1: Volume of Distribution at Steady State (Vss)
LCabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Pharmacokinetic of Cabazitaxel on Cycle 1: Volume of Distribution at Steady State (Vss)6780 ± 32504980 ± 8183930 ± 11705570 ± 2100
SecondaryPharmacokinetic of Cabazitaxel on Cycle 1: Total Plasma Clearance Normalized to Body Surface Area (CL/BSA)
Time frame:
before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion
Reported as:
Mean · L/hr/m^2
Pharmacokinetic of Cabazitaxel on Cycle 1: Total Plasma Clearance Normalized to Body Surface Area (CL/BSA)
L/hr/m^2Cabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Pharmacokinetic of Cabazitaxel on Cycle 1: Total Plasma Clearance Normalized to Body Surface Area (CL/BSA)32.4 ± 18.336.1 ± 6.5831.9 ± 12.649.6 ± 8.56
SecondaryPharmacokinetic of Cabazitaxel on Cycle 1: Volume of Distribution at Steady State Normalized to Body Surface Area (Vss/BSA)
Time frame:
before the start of infusion and 5 minutes before the end of infusion, then 5, 15, 30 minutes, 1, 2, 3, 5, 7, 10, 24, 48, 72, 120 and 168 hours after the end of infusion
Reported as:
Mean · L/m^2
Pharmacokinetic of Cabazitaxel on Cycle 1: Volume of Distribution at Steady State Normalized to Body Surface Area (Vss/BSA)
L/m^2Cabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Pharmacokinetic of Cabazitaxel on Cycle 1: Volume of Distribution at Steady State Normalized to Body Surface Area (Vss/BSA)3530 ± 16502690 ± 4341980 ± 8.833020 ± 1130
SecondaryPharmacokinetic of Gemcitabine on Cycle 1 Day 1: Maximum Plasma Concentration Observed (Cmax)

Blood samples for gemcitabine assay were collected on Day 1 of cycle 1 at the following timepoints: * Cabazitaxel + Gemcitabine: prior the start of cabazitaxel infusion, immediately before the end of gemcitabine infusion, 15, 30 minutes, 1.5, 3.5 and 22.5 hours after the end of gemcitabine infusion; * Gemcitabine + cabazitaxel: prior the start of gemcitabine infusion, immediately before the end of gemcitabine infusion, 15, 30 minutes, 1, 1.5, 2.5, 9 and 23.5 hours after the end of cabazitaxel infusion; Gemcitabine plasma concentrations were determined using validated LC-MS/MS methods with a LLOQ of 50 ng/mL. PK parameters were calculated from plasma concentrations using non-compartmental analysis.

Time frame:
7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Reported as:
Mean · ng/ml
Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Maximum Plasma Concentration Observed (Cmax)
ng/mlCabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Maximum Plasma Concentration Observed (Cmax)14600 ± 605035600 ± 2720011400 ± 327019000 ± 9130
SecondaryPharmacokinetic of Gemcitabine on Cycle 1 Day 1: Time to Maximum Concentration (Tmax)
Time frame:
7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Reported as:
Median · hours (hr)
Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Time to Maximum Concentration (Tmax)
hours (hr)Cabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Time to Maximum Concentration (Tmax)0.49 (0.47 to 0.50)0.38 (0.37 to 0.55)0.60 (0.53 to 0.67)0.42 (0.37 to 0.50)
SecondaryPharmacokinetic of Gemcitabine on Cycle 1 Day 1: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)
Time frame:
7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Reported as:
Mean · ng*hr/ml
Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)
ng*hr/mlCabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)7320 ± 165016000 ± 111006120 ± 33509920 ± 5290
SecondaryPharmacokinetic of Gemcitabine on Cycle 1 Day 1: Area Under the Time Concentration Curve (AUC)
Time frame:
7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Reported as:
Mean · ng*hr/ml
Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Area Under the Time Concentration Curve (AUC)
ng*hr/mlCabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Area Under the Time Concentration Curve (AUC)6290 ± 144021900 ± 108008530 ± NA9970 ± 5310
SecondaryPharmacokinetic of Gemcitabine on Cycle 1 Day 1: Terminal Half-life (t1/2z)
Time frame:
7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Reported as:
Mean · hours
Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Terminal Half-life (t1/2z)
hoursCabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Terminal Half-life (t1/2z)0.295 ± 0.1180.254 ± 0.05700.202 ± NA0.256 ± 0.0933
SecondaryPharmacokinetic of Gemcitabine on Cycle 1 Day 1: Total Plasma Clearance (CL)
Time frame:
7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Reported as:
Mean · L/hr
Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Total Plasma Clearance (CL)
L/hrCabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Total Plasma Clearance (CL)313 ± 12085.1 ± 40.6123 ± NA174 ± 106
SecondaryPharmacokinetic of Gemcitabine on Cycle 1 Day 1: Volume of Distribution at Steady State (Vss)
Time frame:
7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Reported as:
Mean · L
Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Volume of Distribution at Steady State (Vss)
LCabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Volume of Distribution at Steady State (Vss)135 ± 86.228.9 ± 30.447.0 ± NA51.6 ± 28.8
SecondaryPharmacokinetic of Gemcitabine on Cycle 1 Day 1: Total Plasma Clearance Normalized to Body Surface Area (CL/BSA)
Time frame:
7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Reported as:
Mean · L/hr/m^2
Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Total Plasma Clearance Normalized to Body Surface Area (CL/BSA)
L/hr/m^2Cabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Total Plasma Clearance Normalized to Body Surface Area (CL/BSA)159 ± 31.349.8 ± 27.078.4 ± NA96.4 ± 62.8
SecondaryPharmacokinetic of Gemcitabine on Cycle 1 Day 1: Volume of Distribution at Steady State Normalized to Body Surface Area (Vss/BSA)
Time frame:
7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Reported as:
Mean · L/m^2
Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Volume of Distribution at Steady State Normalized to Body Surface Area (Vss/BSA)
L/m^2Cabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Pharmacokinetic of Gemcitabine on Cycle 1 Day 1: Volume of Distribution at Steady State Normalized to Body Surface Area (Vss/BSA)66.5 ± 31.717.3 ± 18.929.9 ± NA28.7 ± 17.4
SecondaryPharmacokinetic of Gemcitabine on Cycle 1 Day 8: Maximum Plasma Concentration Observed (Cmax)

Blood samples for gemcitabine assay were collected on Day 8 of cycle 1 at the following timepoints: * Cabazitaxel + Gemcitabine: prior the start of infusion, immediately before the end of infusion, 15, 30 minutes, 1.5, 3.5 and 22.5 hours after the end of infusion; * Gemcitabine + cabazitaxel: prior the start of infusion, immediately before the end of infusion, 15, 30 minutes, 1, 1.5, 2.5, 9 and 23.5 hours after the end of infusion; Gemcitabine plasma concentrations were determined using validated LC-MS/MS methods with a LLOQ of 50 ng/mL. PK parameters were calculated from plasma concentrations using non-compartmental analysis.

Time frame:
7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Reported as:
Mean · ng/ml
Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Maximum Plasma Concentration Observed (Cmax)
ng/mlCabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Maximum Plasma Concentration Observed (Cmax)10200 ± 28334500 ± 30800—14100 ± 12200
SecondaryPharmacokinetic of Gemcitabine on Cycle 1 Day 8: Time to Maximum Concentration (Tmax)
Time frame:
7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Reported as:
Median · hours (hr)
Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Time to Maximum Concentration (Tmax)
hours (hr)Cabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Time to Maximum Concentration (Tmax)0.52 (0.52 to 0.52)0.45 (0.42 to 0.55)—0.47 (0.40 to 0.48)
SecondaryPharmacokinetic of Gemcitabine on Cycle 1 Day 8: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)
Time frame:
7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Reported as:
Mean · ng*hr/ml
Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)
ng*hr/mlCabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)5530 ± 115015300 ± 11900—7710 ± 6840
SecondaryPharmacokinetic of Gemcitabine on Cycle 1 Day 8: Terminal Half-life (t1/2z)
Time frame:
7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Reported as:
Mean · hours (hr)
Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Terminal Half-life (t1/2z)
hours (hr)Cabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Terminal Half-life (t1/2z)0.222 ± NA0.282 ± 0.0218—0.317 ± 0.113
SecondaryPharmacokinetic of Gemcitabine on Cycle 1 Day 8: Area Under the Time Concentration Curve (AUC)
Time frame:
7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Reported as:
Mean · ng*hr/ml
Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Area Under the Time Concentration Curve (AUC)
ng*hr/mlCabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Area Under the Time Concentration Curve (AUC)6360 ± NA18500 ± 12300—7780 ± 6880
SecondaryPharmacokinetic of Gemcitabine on Cycle 1 Day 8: Total Plasma Clearance (CL)
Time frame:
7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Reported as:
Mean · L/hr
Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Total Plasma Clearance (CL)
L/hrCabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Total Plasma Clearance (CL)262 ± NA110 ± 55.8—252 ± 158
SecondaryPharmacokinetic of Gemcitabine on Cycle 1 Day 8: Volume of Distribution at Steady State (Vss)
Time frame:
7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Reported as:
Mean · L
Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Volume of Distribution at Steady State (Vss)
LCabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Volume of Distribution at Steady State (Vss)104 ± NA36.2 ± 19.4—93.3 ± 51.7
SecondaryPharmacokinetic of Gemcitabine on Cycle 1 Day 8: Total Plasma Clearance Normalized to Body Surface Area (CL/BSA)
Time frame:
7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Reported as:
Mean · L/hr/m^2
Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Total Plasma Clearance Normalized to Body Surface Area (CL/BSA)
L/hr/m^2Cabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Total Plasma Clearance Normalized to Body Surface Area (CL/BSA)157 ± NA62.8 ± 32.7—143 ± 93.3
SecondaryPharmacokinetic of Gemcitabine on Cycle 1 Day 8: Volume of Distribution at Steady State Normalized to Body Surface Area (Vss/BSA)
Time frame:
7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Reported as:
Mean · L/m^2
Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Volume of Distribution at Steady State Normalized to Body Surface Area (Vss/BSA)
L/m^2Cabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Pharmacokinetic of Gemcitabine on Cycle 1 Day 8: Volume of Distribution at Steady State Normalized to Body Surface Area (Vss/BSA)62.2 ± NA20.6 ± 11.6—52.3 ± 28.6
SecondaryPharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Maximum Plasma Concentration Observed (Cmax)

Blood samples collected for gemcitabine assay were used to assay gemcitabine metabolite, 2',2' difluorodeoxyuridine(dFdU). 2',2' difluorodeoxyuridine plasma concentrations were determined using validated LC-MS/MS methods with a LLOQ of 50 ng/mL. PK parameters were calculated from plasma concentrations using non-compartmental analysis.

Time frame:
7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Reported as:
Mean · ng/ml
Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Maximum Plasma Concentration Observed (Cmax)
ng/mlCabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Maximum Plasma Concentration Observed (Cmax)32200 ± 1000032500 ± 1080025500 ± 877021100 ± 5980
SecondaryPharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Time to Maximum Concentration (Tmax)
Time frame:
7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Reported as:
Median · hours
Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Time to Maximum Concentration (Tmax)
hoursCabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Time to Maximum Concentration (Tmax)0.73 (0.50 to 0.77)0.77 (0.47 to 0.83)0.65 (0.53 to 0.77)0.77 (0.50 to 1.47)
SecondaryPharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)
Time frame:
7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Reported as:
Mean · ng*hr/ml
Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)
ng*hr/mlCabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)227000 ± 27500235000 ± 47400167000 ± 47500168000 ± 57000
SecondaryPharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Terminal Half-life (t1/2z)
Time frame:
7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Reported as:
Mean · hours
Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Terminal Half-life (t1/2z)
hoursCabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Terminal Half-life (t1/2z)9.07 ± 2.229.41 ± 0.8377.96 ± 1.8712.1 ± 5.17
SecondaryPharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Area Under the Time Concentration Curve (AUC)
Time frame:
7 to 9 timepoints from start of Day 1 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Reported as:
Mean · ng*hr/ml
Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Area Under the Time Concentration Curve (AUC)
ng*hr/mlCabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 1: Area Under the Time Concentration Curve (AUC)273000 ± 58100285000 ± 61200191000 ± 66900151000 ± 37700
SecondaryPharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Maximum Plasma Concentration Observed (Cmax)

Blood samples collected for gemcitabine assay were used to assay gemcitabine metabolite, 2',2' difluorodeoxyuridine(dFdU). 2',2' difluorodeoxyuridine plasma concentrations were determined using validated LC-MS/MS methods with a LLOQ of 50 ng/mL. PK parameters were calculated from plasma concentrations using non-compartmental analysis.

Time frame:
7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Reported as:
Mean · ng/ml
Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Maximum Plasma Concentration Observed (Cmax)
ng/mlCabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Maximum Plasma Concentration Observed (Cmax)27400 ± 318034800 ± 8630—18700 ± 4740
SecondaryPharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Time to Maximum Concentration (Tmax)
Time frame:
7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Reported as:
Median · hours
Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Time to Maximum Concentration (Tmax)
hoursCabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Time to Maximum Concentration (Tmax)0.69 (0.52 to 0.85)0.68 (0.55 to 1.02)—0.72 (0.70 to 1.00)
SecondaryPharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)
Time frame:
7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Reported as:
Mean · ng*hr/ml
Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)
ng*hr/mlCabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Area Under the Time Concentration Curve From Time 0 To the Real Time Tlast (AUClast)216000 ± 3700287000 ± 77500—141000 ± 26400
SecondaryPharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Terminal Half-life (t1/2z)
Time frame:
7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Reported as:
Mean · hours
Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Terminal Half-life (t1/2z)
hoursCabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Terminal Half-life (t1/2z)7.29 ± 1.118.55 ± 0.820—9.10 ± 0.484
SecondaryPharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Area Under the Time Concentration Curve (AUC)
Time frame:
7 to 9 timepoints from start of Day 8 infusion up to 24h hours after the end of infusion depending on the sequence of treatment on Day 1
Reported as:
Mean · ng*hr/ml
Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Area Under the Time Concentration Curve (AUC)
ng*hr/mlCabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Pharmacokinetic of 2',2' Difluorodeoxyuridine on Cycle 1 Day 8: Area Under the Time Concentration Curve (AUC)240000 ± 11300340000 ± 100000—168000 ± 27600
SecondaryPharmacokinetic of Gemcitabine on Cycle 1: Ratio Day 1/Day 8 for AUClast and AUC

Ratio Day 1/Day 8 for AUClast and AUC were calculated to assess the effect of cabazitaxel on gemcitabine exposure.

Time frame:
Day 1 (7 to 9 timepoints from start of infusion up to 24h hours after the end of infusion) and Day 8 (7 to 9 timepoints from start of infusion up to 24h hours after the end of infusion)
Reported as:
Mean · ratio
Pharmacokinetic of Gemcitabine on Cycle 1: Ratio Day 1/Day 8 for AUClast and AUC
ratioCabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
AUClast1.15 (NA to NA)1.17 (0.661 to 2.49)—1.11 (0.994 to 1.25)
AUC1.15 (NA to NA)1.24 (0.660 to 2.47)—1.11 (0.994 to 1.25)
PrimaryObjective Response Rate With MTD

Objective response was defined as a confirmed complete response (CR) or a confirmed partial response (PR) during the treatment period, based on RECIST 1.1, as assessed by the Investigator. CR: Disappearance of all target lesions, all non-target lesions, and no new lesion. Any pathological lymph nodes must have had reduction in the short axis to \<10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesion. The objective response rate (ORR) was to be calculated as the proportion of participants with confirmed objective response relative to the total number of participants in the analysis population. Due to the inability to determine MTD during the study part 1, the analysis was not performed.

Time frame:
Fron Day 1 up to a maximum of 12 months

No measurements were reported for this outcome.

Adverse events

Collected over from first dose of study medication up to 30 days after the last dose of study medication (maximum follow-up of 68 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cabazitaxel + Gemcitabine Dose Level 0—5/5 (100%)5/5 (100%)
Cabazitaxel + Gemcitabine Dose Level -1—2/5 (40%)5/5 (100%)
Cabazitaxel + Gemcitabine Dose Level -2—2/2 (100%)2/2 (100%)
Gemcitabine + Cabazitaxel Dose Level 0—4/6 (66.7%)6/6 (100%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventCabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
Febrile neutropeniaBlood and lymphatic system disorders1/50/52/21/6
PneumoniaInfections and infestations0/50/51/20/6
SepsisInfections and infestations0/50/51/20/6
ThrombocytopeniaBlood and lymphatic system disorders0/50/51/21/6
Metastases to central nervous systemNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/50/50/20/6
NeutropeniaBlood and lymphatic system disorders1/51/50/20/6
PancytopeniaBlood and lymphatic system disorders1/50/50/21/6
LeukopeniaBlood and lymphatic system disorders0/51/50/20/6
Supraventricular tachycardiaCardiac disorders1/50/50/20/6
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/50/50/20/6
Most frequent other events
Showing 10 of 92
Most frequent other events
EventCabazitaxel + Gemcitabine Dose Level 0Cabazitaxel + Gemcitabine Dose Level -1Cabazitaxel + Gemcitabine Dose Level -2Gemcitabine + Cabazitaxel Dose Level 0
EpistaxisRespiratory, thoracic and mediastinal disorders0/51/52/20/6
FatigueGeneral disorders2/54/51/25/6
NeutropeniaBlood and lymphatic system disorders4/53/51/23/6
DiarrhoeaGastrointestinal disorders2/54/50/22/6
NauseaGastrointestinal disorders1/54/50/22/6
AnaemiaBlood and lymphatic system disorders0/51/50/24/6
Decreased appetiteMetabolism and nutrition disorders2/53/50/24/6
Weight decreasedInvestigations3/51/51/21/6
Urinary tract infectionInfections and infestations0/51/51/20/6
Viral upper respiratory tract infectionInfections and infestations0/50/51/20/6

Baseline characteristics

Age Continuous
Age Continuous(years)Part 1: Cabazitaxel + Gemcitabine Dose Level 0Part 1: Cabazitaxel + Gemcitabine Dose Level -1Part 1: Cabazitaxel + Gemcitabine Dose Level -2Part 1: Gemcitabine + Cabazitaxel Dose Level 0Total
Mean60.8 ± 6.659.2 ± 9.253.0 ± 14.856.3 ± 16.157.7 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Cabazitaxel + Gemcitabine Dose Level 0Part 1: Cabazitaxel + Gemcitabine Dose Level -1Part 1: Cabazitaxel + Gemcitabine Dose Level -2Part 1: Gemcitabine + Cabazitaxel Dose Level 0Total
Female22138
Male332311
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Part 1: Cabazitaxel + Gemcitabine Dose Level 0Part 1: Cabazitaxel + Gemcitabine Dose Level -1Part 1: Cabazitaxel + Gemcitabine Dose Level -2Part 1: Gemcitabine + Cabazitaxel Dose Level 0Total
Asian/Oriental00101
Black01001
Caucasian/White442616
Other10001
Body Surface Area
Body Surface Area(m^2)Part 1: Cabazitaxel + Gemcitabine Dose Level 0Part 1: Cabazitaxel + Gemcitabine Dose Level -1Part 1: Cabazitaxel + Gemcitabine Dose Level -2Part 1: Gemcitabine + Cabazitaxel Dose Level 0Total
Mean1.87 ± 0.321.82 ± 0.211.98 ± 0.421.84 ± 0.121.87 ± 0.24
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)Part 1: Cabazitaxel + Gemcitabine Dose Level 0Part 1: Cabazitaxel + Gemcitabine Dose Level -1Part 1: Cabazitaxel + Gemcitabine Dose Level -2Part 1: Gemcitabine + Cabazitaxel Dose Level 0Total
002114
1532515
200000
Primary Tumor Site
Primary Tumor Site(participants)Part 1: Cabazitaxel + Gemcitabine Dose Level 0Part 1: Cabazitaxel + Gemcitabine Dose Level -1Part 1: Cabazitaxel + Gemcitabine Dose Level -2Part 1: Gemcitabine + Cabazitaxel Dose Level 0Total
Bladder00112
Colon01001
Head/neck01102
Lung21104
Muscle/soft tissue00011
Other01001
Ovaries00011
Pancreas11013
Pelvis00011
Prostate20002
Skin00011
Histological Type
Histological Type(participants)Part 1: Cabazitaxel + Gemcitabine Dose Level 0Part 1: Cabazitaxel + Gemcitabine Dose Level -1Part 1: Cabazitaxel + Gemcitabine Dose Level -2Part 1: Gemcitabine + Cabazitaxel Dose Level 0Total
Adenocarcinoma24028
Squamous cell carcinoma01001
Other303410
Stage at Diagnosis
Stage at Diagnosis(participants)Part 1: Cabazitaxel + Gemcitabine Dose Level 0Part 1: Cabazitaxel + Gemcitabine Dose Level -1Part 1: Cabazitaxel + Gemcitabine Dose Level -2Part 1: Gemcitabine + Cabazitaxel Dose Level 0Total
Stage I00000
Stage II01001
Stage III03014
Stage IV50027
Unknown01337

1 further baseline measures are reported on the registry.

08

Study locations

4 sites
  • Investigational Site Number 840002
    Detroit, Michigan 48201, United States
  • Investigational Site Number 840005
    Cincinnati, Ohio 45267-0542, United States
  • Investigational Site Number 840004
    Philadelphia, Pennsylvania 19111, United States
  • Investigational Site Number 840001
    Nashville, Tennessee 37232, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2013, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2009
First posted
Oct 26, 2009
Start
Nov 2009
Primary completionActual
Oct 2011
CompletionActual
Oct 2011
Results first posted
Sep 11, 2013
Last update
Sep 11, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01001221
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Oct 26, 2009
Start date
Nov 2009
Primary completion
Oct 2011
Completion
Oct 2011
Results posted
Sep 11, 2013
Last update
Sep 11, 2013

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cabazitaxel · Gemcitabine

Start the discussion